Compare TG Therapeutics Inc (TGTX) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vale SA — how do they compare? TG Therapeutics Inc trades at $54.88 (market cap $8.16B), while Vale SA trades at $13.51 (market cap $57.32B). The key difference: Vale SA is far larger — about 7× TG Therapeutics Inc's market cap, and Vale SA pays a 8.87% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Vale SA for 109 Days on average.
| TGTX | VALE | |
|---|---|---|
Market Cap | $8.16B | $57.32B |
Volume | 1,735,121 | 27,996,846 |
Sector | Health | Basic Materials |
52-Week High | $59.06 | $17.82 |
52-Week Low | $26.94 | $10.75 |
Typical Hold Time | 16 Days | 109 Days |
Enterprise Value | $8.37B | $73.56B |
Dividend Yield | — | 8.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
VALE trades at $13.50, down 0.81% with bearish technical signals. The stock has missed earnings expectations for three consecutive quarters, with Q3 2026 EPS expected at $0.42. Revenue declined from $43.8B in 2022 to $38.4B in 2025, though 2026 projections show a slight recovery to $41.2B. Analyst consensus is mixed with 32% buy ratings but a $16.21 price target suggesting 20% upside. Recent news highlights cost pressures and regulatory risks in Brazil.
VALE faces headwinds from declining iron ore margins and rising operational costs, but maintains strong cash flow and dividend payments. The base metals segment shows growth potential, though cyclical exposure and Brazilian regulatory uncertainty pose significant risks. With current valuation metrics appearing reasonable (P/E 26.8, P/B 1.5), the stock offers value for patient investors willing to navigate commodity volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
